Zenosense, Inc. (ZENO) is “One to Watch”
Global biomarker diagnostic testing market projected to reach $53.34 billion by 2021 from $27.95 billion in 2016 Zenosense’s device development incorporates key technology which is patent protected Technology platform could be used to test for a wide variety of common medical conditions that typically are undertaken in laboratory setting at huge expense Point of Care / rapid diagnostics market expected to reach $38.13 billion by 2022 Zenosense, Inc. (OTC: ZENO) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.…